The investment from Sir Terry Leahy and William Currie Group will fund product development and international expansion.
"We’re thankful to our investors for their continued support and for seeing the vision we have for Sirenum in the future. Our continued growth across a variety of industries, as well as new use cases that could not have been foreseen, such as that created by the new vaccination centres, highlight the unique proposition we offer. Moreover, we believe the flexibility of the platform to adjust to unpredictable scenarios, i.e the ability to manage rosters and staff shifts in real time and adjust for sickness or the need to isolate, further underlines why there has never been a better time to invest in workforce management technology like ours. The pandemic has expedited the need for businesses to embrace technology across various parts of their operation, but it is the commercial opportunity for staffing agencies and other employers of shift workers looking for a competitive advantage that will truly propel the use of our technology in the future."
IQ Capital led the Series A investment, which will fund go-to-market expansion and research capabilities.
"We believe in people. And we passionately believe in the impact data and behavioural science can have on human cyber risk management. Our platform is for organisations who ultimately want to do more than rely just on e-learning and phishing simulations. It’s a platform that can grow with them through to when they are ready to measure security behaviour change."
Northstar Ventures and angel investors back Durham information security software provider.
"According to IBM, the average cost of a data breach in 2020 was £2.9 million. Yet most businesses are left with inefficient, costly and paper-heavy manual processes to manage this risk."
The pre-seed round will back research and development as well as sales and marketing expansion.
"Machine learning is more and more integral to products and services we use every day – and to decisions that businesses and governments make about us – but without a widely-accessible way of identifying and eliminating bias, it could cause significant damage to our society by further entrenching discriminatory decision-making despite our best intentions and without us even realising."
The financing round was led by IQ Capital with participation from Hambro Perks and Ascension Ventures.
"This latest round of investment is a great recognition of our customers' success through our breakthrough AI and a product focused approach. With our existing investors reaffirming their support of the company and new investors with vast experience in the life sciences industry coming on board, we are on course to achieve our core mission of improving patient outcomes through a highly profitable and sustainable business model. In the past 12 months, the company has grown 15 times through the successful deployment of PIE in the biopharmaceutical industry, partnerships with healthcare data providers and significant contributions to peer review publications, which demonstrates that we are leading in this sector. This funding will accelerate this success by providing the resources to strengthen the team, explore new use cases, and expand into new markets."
.png)
